The role of SLC transporters in prognosis of breast carcinoma patients

Hlavac V1, Brynychová V1,6, Vaclavíková R1, Ehrlichová M1, Vrana D1,5, Pecha V1, Trnkova M1, Kodet R4, Mrhalová M4, Kubáčková K4, Gut I1 and Soucek P1

1National Institute of Public Health, Czech Republic
2Medicon, Czech Republic
3Biolab Praha, Ltd., Czech Republic
4Motol University Hospital, Czech Republic
5Palacky University Medical School and Teaching Hospital, Czech Republic
6Charles University, Czech Republic

Breast cancer is the second most common cancer in women worldwide. Solute carrier (SLC) transporters can confer to multi-drug resistance via decreased influx of anticancer drugs. The aim of our study was to evaluate expression of SLC transporters in order to find markers of prognosis and/or response of the patients to chemotherapy. Expression profile of twenty-one human SLC transporters was evaluated in 33 post-treatment tumor tissue samples from patients treated by neoadjuvant chemotherapy regimens based on 5-fluorouracil, anthracycline and/or taxanes and in 50 tumor tissue samples taken from patients prior to any treatment. Paired non-tumor control tissues were available from a subset of the patients. SLC19A1 was significantly overexpressed and SLC22A3, SLC47A2, and SLCO1A2 were significantly downregulated in tumors compared with non-tumor control tissues after correction for multiple testing in both sets of patients. Significant association of SLC46A1 transcript levels in tumors with expression of estrogen receptor was found in both sets. Patients with high SLC19A1 levels in the post-treatment set had significantly shorter disease-free survival than patients with low levels. Patients with partial response to neoadjuvant chemotherapy (e.g. responders) had significantly higher intratumoral levels of SLCO1A2 than patients with stable disease or progression (e.g. non-responders). Protein expression of SLCO1A2 was found in tumors but it did not correlate with the transcript levels. SLCO1A2, SLC46A1, and SLC19A1 should be further followed as putative prognostic and predictive biomarkers in breast carcinoma patients.

Biography

Hlaváč V is PhD student at the Third Faculty of Medicine at Charles University in Prague, Czech Republic. He is simultaneously a staff member of the Department of Toxicogenomics in National Institute of Public Health in Prague. He has published four papers in impacted journals regarding his PhD. He regularly attends international congresses and meetings. His major interest is study of biomarkers for individualization of cancer treatment both in patients and in vitro models.

viktor.hlavac@szu.cz